A new study shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma.
source https://www.sciencedaily.com/releases/2020/01/200114123518.htm
source https://www.sciencedaily.com/releases/2020/01/200114123518.htm
Comments
Post a Comment